analyzed (Figures 1 and 2 ). EST interventions were performed under fluoroscopic guidance. All ESTs of HFVM were performed under selective catheter angiography and direct injection, but LFVM with direct injection only. Serious complications were defined as any tissue or functional damage caused by direct injection, distal embolization, or tissue reaction.
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The Prognostic Implications of Diagnosing Frailty and Sarcopenia in Vascular Surgery Practice
Amir A. Ghaffarian, Wylie T. Foss, Brigitte K. Smith, Claire L. Griffen, Mark R. Sarfati, Larry W. Kraiss, Benjamin S. Brooke. University of Utah, Salt Lake City, Utah
Objectives: Frailty and sarcopenia are two related but independent conditions commonly diagnosed in older patients that can be used to predict an individual's ability to tolerate the stress of major vascular surgery. For surgical decision making, however, it is also important to know the prognostic implications associated with these conditions and estimate whether patients will live long enough to benefit from elective procedures. The objective of this study was to assess long-term survival among nonsurgical patients diagnosed with frailty and sarcopenia within an outpatient vascular surgery clinic setting.
Methods: We retrospectively reviewed all patients who presented to the vascular surgery clinic at a single academic hospital between December 2015 and August 2017 who did not subsequently undergo surgery. All patients underwent prospective frailty assessment during their clinic visit using the Clinical Frailty Scale. Patients who underwent an abdominal computed tomography scan within the prior 12 months were included in the analysis. A single axial CT-image at the most caudal end of the third lumbar vertebrae was assessed to measure crosssectional areas (in centimeters squared) of skeletal muscle, and sarcopenia was defined using established criteria of <52.4 cm 2 /m 2 for male and <38.5 cm 2 /m 2 for female patients. After stratifying patients by frailty and sarcopenia diagnoses, the association with all-cause mortality was analyzed using Kaplan-Meier curves and log-rank tests.
Results: A total of 248 patients were identified, of which 48 (19%) were diagnosed as frail and 98 (40%) met CT diagnostic criteria for sarcopenia. The median follow-up after CT imaging was 1.5 years (interquartile range, 1.1-2.2 years). When further stratified, 72 patients (29%) met only sarcopenia criteria, 22 (9%) met only frailty criteria, and 26 (11%) met criteria for both sarcopenia and frailty. Patients diagnosed with either sarcopenia or frailty were older (mean, 67 years vs 60 years; P < .001) and more likely to be male (57% vs 36%; P < .001) and have chronic obstructive pulmonary disease (67% vs 45%; P ¼ .013). When compared with patients without sarcopenia or frailty, long-term survival was significantly decreased for patients diagnosed with either sarcopenia or frailty (Fig; log-rank test P < .01). However, patients diagnosed with both sarcopenia and frailty were found to have the highest mortality rate at the 1-year follow-up.
Conclusions: Frailty and sarcopenia are common conditions among patients presenting to outpatient vascular surgery clinics that can be used to predict long-term patient survival. Identifying patients with both frailty and sarcopenia portends the worst survival, and should be taken into consideration when deciding whether to proceed with elective vascular surgery procedures. Objectives: Thoracoabdominal aneurysm (TAAA) extent 4 aneurysms share a common region of the visceral aorta with extents 2 and 3, with 3, extending proximally to the sixth intercostal space and two further to the left subclavian artery. We sought to determine how proximal extension affects outcome risk incrementally to the extent 4 visceral segment. Risk factor adjustment was performed to separate these effects from underlying disease and surgical risk factors.
Methods: Underlying vascular disease risk was estimated using risk factors of the National Cholesterol Education Program coronary heart disease risk equivalents. These are coronary heart disease, coronary artery disease, peripheral arterial disease, AAA, diabetes mellitus, and chronic kidney disease. We identified further risk factors empirically with regression methods. Aggregate risk equivalent was compared between extents by one-way analysis of variance.
Results: Between 1991 and 2017, we performed 879 repairs with TAAA extents involving the visceral segment with extent 2 (n ¼ 329), 3 (n ¼ 196), or 4 (n ¼ 354) disease. The mean age was 66 6 15 years and 35% were women (309/879). Among the vascular disease risk-equivalent factors, TAAA extent 4 had significantly higher prior AAA (27% vs 14% vs 21%; P < .0001), chronic kidney disease (P < .0007), diabetes mellitus (P < .0001), PVD (P < .003) and coronary artery disease (P < .0001) compared with TAAA extent 2 and TAAA extent 3. Vascular disease risk burden was greatest in TAAA extent 4, intermediate in TAAA extent 3, and least in TAAA extent 2, with mean scores of 1.77, 1.49, and 1.01, respectively (analysis of variance P < .0001; all pairwise comparisons P < .05). e198 Abstracts
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June 2018 Unadjusted 30-day mortality was 16% in extent 2, 26% in extent 3, 19% in extent 4 disease (P < .03 for overall heterogeneity; Fig and Table) ; extent 3 was different from extent 2 and extent 4 (P < .009) but extent 2 versus extent 4 were not different from each other (P ¼ .44). Vascular disease risk-burden was significant independent predictor of 30-day mortality, and for each 1-point increase in burden score, the odds of 30-day mortality increased by 1.5 time (P < .0001). After adjustment for other risk factors, 30-day mortality was significantly lower in extent 4 disease (odds ratio, 0.49; P < .008). Similarly, adjusted paraplegia rates were significantly lower in TAAA extent 4 disease (odds ratio, 0.22; P < .0001).
Conclusions:
The apparent high mortality and morbidity risk associated with extent 4 TAAA could be attributed to the increased baseline vascular disease burden, especially prior AAA repair, compared with TAAA extent 2 and TAAA extent 3 disease.
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Risk Score for Groin Access Complication in Ultrasound-Guided Percutaneous Aortic Procedures
Patric Liang, Thomas F. X. O'Donnell, Andy Lee, Nicholas J. Swerdlow, Chun Li, Mark C. Wyers, Allen Hamdan, Marc L. Schermerhorn. Beth Israel Deaconess Medical Center, Boston, Mass
Objectives: Ultrasound-guided access for percutaneous endovascular aortic procedures has been increasingly used. We developed a prediction model to risk stratify patients for access site complications following ultrasound-guided percutaneous approach.
Methods: We performed a retrospective institutional review of consecutive patients who underwent percutaneous endovascular repair of emergent and elective aortic pathology, from 2014 to 2016. We excluded patients undergoing initial femoral artery (FA) cutdown, endoleak treatment, or aortic arch reconstruction. Our primary outcome was groin access site complication, which included bleeding, thrombosis, infection, and conversion to femoral cutdown. We created a 15-point risk model for groin access complication using logistic regression.
Results: We identified 292 FAs from 152 patients undergoing endovascular aortic repair procedures (endovascular aortic aneurysm repair 76.8%, fenestrated endovascular aortic aneurysm repair 7.7%, thoracic endovascular aortic aneurysm repair 15.5%). Surgeons used percutaneous access in 97.3% of FAs (2.7% underwent planned femoral endarterectomy), with 100% ultrasound use and 100% initial success rate. Superficial 
